60 Degrees Pharmaceuticals and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
60 Degrees Pharmaceuticals and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
CANF: ORLANDO, FL / ACCESSWIRE / November 22, 2024 / RedChip Companies will air interviews with 60 Degrees Pharmaceuticals, Inc. (Nasdaq:SXTP) and Can-Fite BioPharma Ltd. (NYSE American:CANF)(TASE:CANF) on the RedChip Small Stocks, Big Money show, a sponsored program on Bloomberg TV, this Saturday, November 23, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.
佛羅里達州奧蘭多 / ACCESSWIRE / 2024年11月22日 / RedChip Companies將在Bloomberg TV播出與60 Degrees Pharmaceuticals, Inc.（納斯達克：SXTP）和can-fite biopharma Ltd.（紐交所：CANF）（特拉維夫證券交易所：CANF）的訪談，這檔節目是RedChip小型股票，大筆資金節目，定於11月23日星期六晚上7點（東部時間）播出。Bloomberg TV在美國預計有7300萬家庭可收看。
Access the interviews in their entirety at:
Soligenix:
SXTP:
CANF:
SXTP:
CANF:
In an exclusive interview, Geoffrey Dow, CEO and President of 60 Degrees Pharmaceuticals, appears on the RedChip Small Stocks Big Money show on Bloomberg TV to discuss the company's mission to develop and commercialize new therapies for infectious diseases. He highlights the FDA-approved antimalarial drug ARAKODA (tafenoquine) and outlines plans to expand its indications to address other diseases, including babesiosis. Dow also emphasizes the company's commitment to addressing unmet medical needs and improving global health outcomes.
在一次獨家訪談中，60 Degrees Pharmaceuticals的首席執行官兼總裁Geoffrey Dow出現在Bloomberg TV的RedChip小型股票大筆資金節目中，討論公司的使命，即開發和商業化針對傳染病的新療法。他強調了FDA批准的抗瘧藥ARAOKDA（tafenoquine），並概述了將其適應症擴展以應對其他疾病（包括巴貝斯蟲病）的計劃。Dow還強調了公司滿足未滿足醫療需求和改善全球健康結果的承諾。
Motti Farbstein, CEO of Can-Fite, appears on the RedChip Small Stocks Big Money show on Bloomberg TV to discuss the company's advanced clinical-stage drug development efforts targeting multi-billion-dollar markets in oncology and inflammatory diseases. He provides insights into Can-Fite's innovative oral drug platform and shares updates on their late-stage clinical pipeline, highlighting the potential impact on patient care and significant potential upcoming milestone and royalty payments.
Can-Fite的首席執行官Motti Farbstein出現在Bloomberg TV的RedChip小型股票大筆資金節目中，討論公司針對腫瘤和炎症疾病的數十億美元市場的愛文思控股臨床階段藥物開發努力。他提供了對Can-Fite創新口服藥物平台的見解，並分享了其後期臨床項目的最新進展，強調了對患者護理的潛在影響和重要的即將到來的里程碑及版稅支付。
60 Degrees Pharmaceuticals and Can-Fite BioPharma are clients of RedChip Companies. Please read our full disclosure at .
60 Degrees Pharmaceuticals和can-fite biopharma是RedChip Companies的客戶。請閱讀我們的完整披露。
About 60 Degrees Pharmaceuticals, Inc.
60 Degrees Pharmaceuticals, Inc., founded in 2010, specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases that affect the lives of millions of people. 60 Degrees Pharmaceuticals, Inc. achieved FDA approval of its lead product, ARAKODA (tafenoquine), for malaria prevention, in 2018. 60 Degrees Pharmaceuticals, Inc. also collaborates with prominent research organizations in the U.S., Australia, and Singapore. The 60 Degrees Pharmaceuticals, Inc. mission has been supported through in-kind funding from the U.S. Department of Defense and private institutional investors including Knight Therapeutics Inc., a Canadian-based pan-American specialty pharmaceutical company. 60 Degrees Pharmaceuticals, Inc. is headquartered in Washington D.C., with a majority-owned subsidiary in Australia. Learn more at .
關於60度製藥公司。
60度藥品公司成立於2010年，專注於開發和營銷用於治療和預防影響數百萬人生活的傳染病的新藥物。60度藥品公司於2018年獲得FDA對其首個產品ARAKODA（塔氟喹啉）用於瘧疾預防的批准。60度藥品公司還與美國、澳洲和新加坡的知名研究機構合作。60度藥品公司的使命得到了美國國防部和包括加拿大泛美專業藥品公司Knight Therapeutics Inc.在內的私人機構投資者的實物資助。60度藥品公司總部位於華盛頓D.C.，在澳洲擁有一家多數控股的子公司。了解更多信息請訪問 .
About Can-Fite BioPharma Ltd.
Can-Fite BioPharma Ltd.（NYSE：CANF）（TASE：CANF）是一家先進的臨床階段藥物開發公司，擁有設計用於治療肝癌和炎症性疾病的多十億美元市場的平台技術。公司的核心藥物候選，Piclidenoson，最近在牛皮癬第3期試驗中報告了業績排名，並有望開始關鍵性第3期。Can-Fite的肝癌和肝臟藥物Namodenoson正在評估治療代謝性功能障礙相關脂肪肝病（MASH）等級的2b期試驗，正在進行用於肝細胞癌（HCC）的第3期關鍵性試驗，公司正在規劃胰腺癌的2a期研究。Namodenoson已獲得美國和歐洲的孤兒藥指定，並被美國食品和藥品管理局授予作爲HCC的二線治療快速通道。Namodenoson還顯示了概念證明，有可能治療其他癌症，包括結腸癌、前列腺癌和黑色素瘤。公司的第三種藥物候選CF602，在治療勃起功能障礙方面表現出有效性。這些藥物在臨床研究中已經在超過1600名患者中得到了極好的安全性評價。有關更多信息，請訪問公司網站。
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF) is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, liver, and inflammatory disease. The Company's lead drug candidate, Piclidenoson recently reported topline results in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is being evaluated in a Phase IIb trial for the treatment of MASH a Phase III trial for hepatocellular carcinoma (HCC), and the Company is planning a Phase IIa study in pancreatic cancer. Namodenoson has been granted Orphan Drug Designation in the U.S. and Europe and Fast Track Designation as a second line treatment for HCC by the U.S. Food and Drug Administration. Namodenoson has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma. CF602, the Company's third drug candidate, has shown efficacy in the treatment of erectile dysfunction. These drugs have an excellent safety profile with experience in over 1,600 patients in clinical studies to date. For more information please visit: .
can-fite biopharma有限公司（紐約美國：CANF）（特拉維夫證券交易所：CANF）是一家擁有面向治療癌症、肝臟和炎症疾病的數十億美元市場的平台技術的先進臨床階段藥物開發公司。該公司的主力候選藥物Piclidenoson最近在銀屑病三期試驗中報告了前線結果。Can-Fite的肝臟藥物Namodenoson正在進行脂肪肝(非酒精性脂肪性肝病)二期b期試驗和肝細胞癌的三期試驗，並計劃在胰腺癌中進行二期a研究。Namodenoson已被美國和歐洲授予特種藥品認定，並被美國食品和藥物管理局授予作爲肝細胞癌的二線治療的快速通道認定。Namodenoson還顯示了概念驗證，有望治療其他癌症，包括結腸癌、前列腺癌和黑色素瘤。公司的第三種藥物候選藥CF602在治療勃起功能障礙方面顯示了療效。這些藥物在迄今爲止的臨床研究中在超過1600名患者中具有良好的安全性。更多信息請訪問：。
About RedChip Companies
關於RedChip公司
RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. For 32 years, RedChip has delivered concrete, measurable results for its clients. Our newsletter, Small Stocks, Big Money, is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, Small Stocks, Big Money, which airs weekly on Bloomberg US; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more.
RedChip Companies是一家國際投資者關係、媒體和研究公司，專注於微型股和小型股公司。32年來，RedChip已爲其客戶提供了具體可衡量的成果。我們的每週在線電子報Small Stocks, Big Money發送給6萬名投資者。RedChip已經開發出業內最全面的服務平台，爲微型股和小型股公司提供以下服務：其股票研究的全球分發網絡；在美國主要城市進行的零售和機構路演；向股票經紀人、RIAs、機構和家族辦公室進行外出營銷；數字媒體投資者關係平台已經產生了數百萬的獨立投資者瀏覽量；投資者網絡研討會和群體電話；電視節目《Small Stocks, Big Money》，每週在Bloomberg美國播出；在本地和全國市場播放電視廣告；公司和產品視頻；網站設計；以及傳統的投資者關係服務，包括撰寫新聞稿、制定投資者演示文稿、季度電話會議腳本撰寫、戰略諮詢、資本籌集等。欲了解更多RedChip的產品和服務，請訪問：
To learn more about RedChip's products and services, please visit:
要了解更多關於RedChip公司產品和服務的信息，請訪問以下網站：
"Discovering Tomorrow's Blue Chips Today"
「發現明日的藍籌股」
Follow RedChip on LinkedIn:
在LinkedIn上關注RedChip：
Follow RedChip on Facebook:
在Facebook上關注RedChip：
Follow RedChip on Instagram:
在Instagram上關注RedChip：
Follow RedChip on Twitter:
在Twitter上關注RedChip：
Follow RedChip on YouTube:
在YouTube上關注RedChip：
Follow RedChip on Rumble:
在Rumble上關注RedChip：
Subscribe to our Mailing List:
訂閱我們的郵件列表：
Contact:
聯繫方式：
Dave Gentry
RedChip Companies Inc.
1-407-644-4256
info@redchip.com
Dave Gentry
RedChip Companies Inc.
1-407-644-4256
info@redchip.com
SOURCE: RedChip
來源：RedChip
譯文內容由第三人軟體翻譯。
